Richard Charles Coulon

Accuitis, Inc. operates as a pre-clinical-stage biopharmaceutical company. It develops first-in-class drug therapies to treat chronic diseases of the skin and eye. The firm engages in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. The company was founded on December 13, 2011 and is headquartered in Alpharetta, GA.

Accuitis, Inc. operates as a pre-clinical-stage biopharmaceutical company. It develops first-in-class drug therapies to treat chronic diseases of the skin and eye. The firm engages in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. The company was founded on December 13, 2011 and is headquartered in Alpharetta, GA.

Accuitis, Inc. operates as a pre-clinical-stage biopharmaceutical company. It develops first-in-class drug therapies to treat chronic diseases of the skin and eye. The firm engages in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. The company was founded on December 13, 2011 and is headquartered in Alpharetta, GA.

Accuitis, Inc. operates as a pre-clinical-stage biopharmaceutical company. It develops first-in-class drug therapies to treat chronic diseases of the skin and eye. The firm engages in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. The company was founded on December 13, 2011 and is headquartered in Alpharetta, GA.

Accuitis, Inc. operates as a pre-clinical-stage biopharmaceutical company. It develops first-in-class drug therapies to treat chronic diseases of the skin and eye. The firm engages in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. The company was founded on December 13, 2011 and is headquartered in Alpharetta, GA.